Home Tags AbbVie
AbbVie just stopped enrolling patients in a late-stage trial of a high-profile lung cancer drug after patients had shorter survival results on the drug.
A company that’s taking a new approach to tackling Alzheimer’s is moving into human trials after raising $133 million
Biotech startup Alector is getting ready to put its first batch of neurodegenerative drugs into humans after raising an additional $133 million. Alector is developing treatments that harness the body's immune system to tackle conditions like Alzheimer's, and other forms of dementia.
A new treatment for a condition that can feel like tiny people skating on razor blades in your stomach and affects an estimated 200 million women just...
The FDA just approved elagolix, a new treatment for women living with endometriosis. Endometriosis, a condition that affects millions of women, occurs when tissue from the uterus grows outside of it, leading to cysts, heavy bleeding, and scarring.
‘Nobody’s talking about’ 2 medical conditions that affect 8 million women in America — but that could be about to change
The drugs in development are to treat two major women's health conditions: endometriosis and uterine fibroids.
The Reputation Institute took a look at what the general public thought of 17 major pharmaceutical companies. Here's who came out on top.
Here’s the cancer data that led AbbVie to make the 2nd-largest acquisition in the history of venture capital
Stemcentrx wants to target cancer stem cells to treat a form of lung cancer — and we just got more data showing how it works.
The Reputation Institute took a look at what the general public thought of 14 major pharmaceutical companies. Here's who came out on top.
The second-largest acquisition in the history of venture capital happened today — here’s why a pharma giant paid $10 billion for a startup...
Stemcentrx, a former Sillicon Valley unicorn, is developing drugs that go after cancer stem cells. Here's why AbbVie thinks that's a good idea.
AbbVie's venetoclax just got approved for chronic lymphocytic leukemia in people with a specific genetic tweak called a 17p deletion.
New York’s attorney general is investigating whether insurance companies may be unfairly limiting coverage for a costly drug
The New York state Attorney General's office on Wednesday asked 16 health insurers for information related to patients who've been denied hepatitis C drugs.